The PharmD/MD Dual-Degree Program and Its Potential Value in the Pharmaceutical Industry

Khushbu S. Shah, Upasana Marwah, Kristina Bundra, Carol S. Goldin, Michael Toscani, Joseph Barone, John Colaizzi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The first dual-degree program combining both the doctor of pharmacy (PharmD) and the doctor of medicine (MD) degrees was designed and launched by Rutgers, The State University of New Jersey, in academic year 2013-2014. This joint effort was led by the Ernest Mario School of Pharmacy (EMSOP) and the Robert Wood Johnson Medical School (RWJMS) to combine expertise in both diagnostic and treatment facets of health care and to prepare graduates for leadership roles in providing and managing comprehensive patient care in a variety of settings. One area of potential value of these skill sets is the drug development industry. A survey was conducted among pharmaceutical executive stakeholders associated with a postdoctoral training program to assess the perceived value of this new dual-degree skill set and to identify particular functions where the combined training has its best fit. Results indicate that the combined nature of this training is highly valued in this setting, especially in the areas of clinical pharmacology, drug safety and pharmacovigilance, medical affairs/strategy, and medical science liaisons. Future monitoring of graduates will further define the value of this dual degree in this and other health care settings.

Original languageEnglish (US)
Pages (from-to)839-845
Number of pages7
JournalTherapeutic Innovation and Regulatory Science
Volume50
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Drug Industry
Medicine
Pharmacy Schools
Delivery of Health Care
Pharmacovigilance
Clinical Pharmacology
Medical Schools
Pharmaceutical Preparations
Patient Care
Safety
Education
Therapeutics
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Keywords

  • PharmD/MD
  • drug development
  • dual degree
  • pharma
  • pharmaceutical industry

Cite this

@article{99cebc1732904782a91eb1ad600830d0,
title = "The PharmD/MD Dual-Degree Program and Its Potential Value in the Pharmaceutical Industry",
abstract = "The first dual-degree program combining both the doctor of pharmacy (PharmD) and the doctor of medicine (MD) degrees was designed and launched by Rutgers, The State University of New Jersey, in academic year 2013-2014. This joint effort was led by the Ernest Mario School of Pharmacy (EMSOP) and the Robert Wood Johnson Medical School (RWJMS) to combine expertise in both diagnostic and treatment facets of health care and to prepare graduates for leadership roles in providing and managing comprehensive patient care in a variety of settings. One area of potential value of these skill sets is the drug development industry. A survey was conducted among pharmaceutical executive stakeholders associated with a postdoctoral training program to assess the perceived value of this new dual-degree skill set and to identify particular functions where the combined training has its best fit. Results indicate that the combined nature of this training is highly valued in this setting, especially in the areas of clinical pharmacology, drug safety and pharmacovigilance, medical affairs/strategy, and medical science liaisons. Future monitoring of graduates will further define the value of this dual degree in this and other health care settings.",
keywords = "PharmD/MD, drug development, dual degree, pharma, pharmaceutical industry",
author = "Shah, {Khushbu S.} and Upasana Marwah and Kristina Bundra and Goldin, {Carol S.} and Michael Toscani and Joseph Barone and John Colaizzi",
year = "2016",
month = "11",
day = "1",
doi = "10.1177/2168479016652926",
language = "English (US)",
volume = "50",
pages = "839--845",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "6",

}

The PharmD/MD Dual-Degree Program and Its Potential Value in the Pharmaceutical Industry. / Shah, Khushbu S.; Marwah, Upasana; Bundra, Kristina; Goldin, Carol S.; Toscani, Michael; Barone, Joseph; Colaizzi, John.

In: Therapeutic Innovation and Regulatory Science, Vol. 50, No. 6, 01.11.2016, p. 839-845.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The PharmD/MD Dual-Degree Program and Its Potential Value in the Pharmaceutical Industry

AU - Shah, Khushbu S.

AU - Marwah, Upasana

AU - Bundra, Kristina

AU - Goldin, Carol S.

AU - Toscani, Michael

AU - Barone, Joseph

AU - Colaizzi, John

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The first dual-degree program combining both the doctor of pharmacy (PharmD) and the doctor of medicine (MD) degrees was designed and launched by Rutgers, The State University of New Jersey, in academic year 2013-2014. This joint effort was led by the Ernest Mario School of Pharmacy (EMSOP) and the Robert Wood Johnson Medical School (RWJMS) to combine expertise in both diagnostic and treatment facets of health care and to prepare graduates for leadership roles in providing and managing comprehensive patient care in a variety of settings. One area of potential value of these skill sets is the drug development industry. A survey was conducted among pharmaceutical executive stakeholders associated with a postdoctoral training program to assess the perceived value of this new dual-degree skill set and to identify particular functions where the combined training has its best fit. Results indicate that the combined nature of this training is highly valued in this setting, especially in the areas of clinical pharmacology, drug safety and pharmacovigilance, medical affairs/strategy, and medical science liaisons. Future monitoring of graduates will further define the value of this dual degree in this and other health care settings.

AB - The first dual-degree program combining both the doctor of pharmacy (PharmD) and the doctor of medicine (MD) degrees was designed and launched by Rutgers, The State University of New Jersey, in academic year 2013-2014. This joint effort was led by the Ernest Mario School of Pharmacy (EMSOP) and the Robert Wood Johnson Medical School (RWJMS) to combine expertise in both diagnostic and treatment facets of health care and to prepare graduates for leadership roles in providing and managing comprehensive patient care in a variety of settings. One area of potential value of these skill sets is the drug development industry. A survey was conducted among pharmaceutical executive stakeholders associated with a postdoctoral training program to assess the perceived value of this new dual-degree skill set and to identify particular functions where the combined training has its best fit. Results indicate that the combined nature of this training is highly valued in this setting, especially in the areas of clinical pharmacology, drug safety and pharmacovigilance, medical affairs/strategy, and medical science liaisons. Future monitoring of graduates will further define the value of this dual degree in this and other health care settings.

KW - PharmD/MD

KW - drug development

KW - dual degree

KW - pharma

KW - pharmaceutical industry

UR - http://www.scopus.com/inward/record.url?scp=84992449654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992449654&partnerID=8YFLogxK

U2 - 10.1177/2168479016652926

DO - 10.1177/2168479016652926

M3 - Article

VL - 50

SP - 839

EP - 845

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 6

ER -